11:08 AM EDT, 07/24/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were weaker late Wednesday morning, declining 0.53% to 1,418.08 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by medical device maker EDAP TMS ( EDAP ) and biopharmaceutical company Grifols ( GRFS ) , which rose 3.2% and 3% respectively. They were followed by biopharmaceutical company Genfit ( GNFT ) and financial services company Banco Santander (SAN), which increased 2.6% and 2.5% respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications ( SQNS ) and biotech firm BioNTech (BNTX), which dropped 4.2% and 2.8% respectively. They were followed by biopharmaceutical company Cellectis ( CLLS ) and software firm SAP (SAP), which were down 2.4% and 2% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics ( ADAP ) and biotech firm Autolus Therapeutics ( AUTL ) , which were up 3.1% and 2.7% respectively. They were followed by biopharmaceutical companies TC Biopharm ( TCBP ) , which rose 1.9%.

The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana ( NCNA ) and Akari Therapeutics ( AKTX ) , which shed 16% and 6.9% respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals ( BDRX ) and Mereo BioPharma Group ( MREO ) , which were down 3.1% and 2.6% respectively.